LOGIN  |  REGISTER
Amneal Pharmaceuticals
Viking Therapeutics

Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

May 06, 2025 | Last Trade: US$0.67 0.03 -3.87

BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025.

Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results.

Conference Details:
Conference Date: Monday, May 12, 2025
Conference Time: 4:30 PM ET
Conference dial-in: 888-506-0062
International dial-in: 973-528-0011
Passcode: 828748
Conference Call Name: Xtant Medical Q1 2025 Financial Results
Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/52428

Following the live call, a replay will be available on the Company's website, https://xtantmedical.com/, under "Investor Info."

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of "honoring the gift of donation so that our patients can live as full and complete a life as possible" is the driving force behind our company. Xtant Medical Holdings, Inc. ( www.xtantmedical.com ) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States , and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page